Meeting News Coverage

Fatty liver disease may overtake HCV as key cause of liver transplant, AASLD president says

November 2, 2013
WASHINGTON — Once considered largely benign, fatty liver disease may overtake hepatitis C as the leading cause of liver transplant…
Meeting News Coverage

Annual Liver Meeting begins this weekend

November 1, 2013 will present live coverage of the American Association for the Study of Liver Diseases’ annual Liver Meeting running through Tuesday…
Meeting News Coverage

Physicians not following CDC guides on HCV screening

October 31, 2013
SAN DIEGO — Despite new guidelines issued by the CDC in 2012 calling for hepatitis C screening for everyone born between 1945 and 1965…
Meeting News Coverage

PI-based therapy for hepatitis C showed promising results in real-life urban setting

October 29, 2013
SAN DIEGO — The success of protease inhibitor-based therapy among African-Americans with hepatitis C can be reproduced outside of clinical…
FDA advisory panel decisions

Panel recommends FDA approve sofosbuvir for hepatitis C

October 25, 2013
The FDA’s Antiviral Drugs Advisory Committee today recommended approval of sofosbuvir, a first-in-class, once-daily oral nucleotide inhibitor from…
FDA advisory panel decisions

FDA panel unanimously approves simeprevir for HCV genotype 1

October 24, 2013
The FDA’s Antiviral Drugs Advisory Committee today voted that available data overwhelmingly supports approval of simeprevir in combination with…
FDA News

HCV drugs simeprevir, sofosbuvir earn positive FDA reviews before advisory board votes

October 23, 2013
Two hepatitis C drugs, simeprevir and sofosbuvir, received promising internal FDA reviews on the eve of advisory board meetings at which government…
Meeting News Coverage

Birth cohort alone insufficient as HCV screening criterion

October 14, 2013
SAN DIEGO — Screening for hepatitis C according to age alone was not as effective in detecting infection as risk-based screening in a study…
Meeting News Coverage

Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

October 11, 2013
SAN FRANCISCO – Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced…
Meeting News Coverage

Tattoos, drug use primary HCV risk factors in Mexican prison population

October 10, 2013
SAN FRANCISCO – Prison inmates in Mexico had a high prevalence of hepatitis C infection, with tattoos and drug use, particularly injected…